VERBRUGGEN, L. C., Y. H. WANG, S. H. ARMENIAN, M. J. EHRHARDT, H. J. H. VAN DER PAL, E. C. VAN DALEN, J. W. VAN AS, E . BARDI, K. BAUST, C. BERGER, E. CASTAGNOLA, K. A. DEVINE, J . GEBAUER, J. G. MARCHAK, A. W. GLASER, A. H. GROLL, G. M. HAEUSLER, J. DEN HARTOGH, R. HAUPT, L. HJORTH, M. KATO, Tomáš KEPÁK, M. M. W. KOOPMAN, T. LANGER, M. MAEDA, G. MICHEL, M. MURACA, P. C. NATHAN, S. R. VAN DEN OEVER, V. PAVASOVIC, S. SATO, F. SCHULTE, L. L. SUNG, W. TISSING, A. UYTTEBROECK, R. L. MULDER, C. KUEHNI, R. SKINNER, M. M. HUDSON and L. C. M. KREMER. Guidance regarding COVID-19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group. PEDIATRIC BLOOD & CANCER. HOBOKEN: WILEY, 2020, vol. 67, No 12, p. 1-10. ISSN 1545-5009. Available from: https://dx.doi.org/10.1002/pbc.28702.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Guidance regarding COVID-19 for survivors of childhood, adolescent, and young adult cancer: A statement from the International Late Effects of Childhood Cancer Guideline Harmonization Group
Authors VERBRUGGEN, L. C. (528 Netherlands, guarantor), Y. H. WANG (528 Netherlands), S. H. ARMENIAN (840 United States of America), M. J. EHRHARDT (840 United States of America), H. J. H. VAN DER PAL (528 Netherlands), E. C. VAN DALEN (528 Netherlands), J. W. VAN AS (528 Netherlands), E . BARDI (40 Austria), K. BAUST (276 Germany), C. BERGER (250 France), E. CASTAGNOLA (380 Italy), K. A. DEVINE (840 United States of America), J . GEBAUER (276 Germany), J. G. MARCHAK (840 United States of America), A. W. GLASER (826 United Kingdom of Great Britain and Northern Ireland), A. H. GROLL (276 Germany), G. M. HAEUSLER (36 Australia), J. DEN HARTOGH (528 Netherlands), R. HAUPT (380 Italy), L. HJORTH (752 Sweden), M. KATO (392 Japan), Tomáš KEPÁK (203 Czech Republic, belonging to the institution), M. M. W. KOOPMAN (528 Netherlands), T. LANGER (276 Germany), M. MAEDA (392 Japan), G. MICHEL (756 Switzerland), M. MURACA (380 Italy), P. C. NATHAN (124 Canada), S. R. VAN DEN OEVER (528 Netherlands), V. PAVASOVIC (826 United Kingdom of Great Britain and Northern Ireland), S. SATO (392 Japan), F. SCHULTE (124 Canada), L. L. SUNG (124 Canada), W. TISSING (528 Netherlands), A. UYTTEBROECK (56 Belgium), R. L. MULDER (528 Netherlands), C. KUEHNI (756 Switzerland), R. SKINNER (826 United Kingdom of Great Britain and Northern Ireland), M. M. HUDSON (840 United States of America) and L. C. M. KREMER (528 Netherlands).
Edition PEDIATRIC BLOOD & CANCER, HOBOKEN, WILEY, 2020, 1545-5009.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30209 Paediatrics
Country of publisher United States of America
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 3.167
RIV identification code RIV/00216224:14110/20:00116603
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1002/pbc.28702
UT WoS 000572077700001
Keywords in English childhood adolescent and young adult (CAYA) cancer survivors; COVID-19; late effects of cancer treatment
Tags 14110321, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 5/1/2021 13:30.
Abstract
Childhood, adolescent, and young adult (CAYA) cancer survivors may be at risk for a severe course of COVID-19. Little is known about the clinical course of COVID-19 in CAYA cancer survivors, or if additional preventive measures are warranted. We established a working group within the International Late Effects of Childhood Cancer Guideline Harmonization Group (IGHG) to summarize existing evidence and worldwide recommendations regarding evidence about factors/conditions associated with risk for a severe course of COVID-19 in CAYA cancer survivors, and to develop a consensus statement to provide guidance for healthcare practitioners and CAYA cancer survivors regarding COVID-19.
PrintDisplayed: 23/8/2024 18:01